KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) Research & Development (2016 - 2026)

Edwards Lifesciences has reported Research & Development over the past 17 years, most recently at $267.7 million for Q4 2025.

  • For Q4 2025, Research & Development fell 1.25% year-over-year to $267.7 million; the TTM value through Dec 2025 reached $1.1 billion, up 2.49%, while the annual FY2025 figure was $1.1 billion, 2.49% up from the prior year.
  • Research & Development for Q4 2025 was $267.7 million at Edwards Lifesciences, down from $280.7 million in the prior quarter.
  • Over five years, Research & Development peaked at $280.7 million in Q3 2025 and troughed at $130.6 million in Q4 2022.
  • A 5-year average of $243.4 million and a median of $247.2 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 43.9% in 2022 and later surged 85.38% in 2023.
  • Year by year, Research & Development stood at $232.8 million in 2021, then plummeted by 43.9% to $130.6 million in 2022, then soared by 85.38% to $242.1 million in 2023, then increased by 11.98% to $271.1 million in 2024, then dropped by 1.25% to $267.7 million in 2025.
  • Business Quant data shows Research & Development for EW at $267.7 million in Q4 2025, $280.7 million in Q3 2025, and $276.2 million in Q2 2025.